6th August 2026 – FDA Tentative Approval for Omcazio: A New Cabozantinib Capsule Formulation Handa Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to Omcazio (cabozantinib) capsules, a novel alternate-salt formulation of the well-established tyrosine kinase inhibitor (TKI). Developed under the Section 505(b)(2) regulatory pathway, Omcazio represents a pharmacological evolution … Continue reading CABOMETYX® (cabozantinib) for pNET and epNET